Unity Biotechnology, Inc. (UBX) News

Unity Biotechnology, Inc. (UBX): $0.79

-0.03 (-3.11%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add UBX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 392

in industry

Filter UBX News Items

UBX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

UBX News Highlights

  • For UBX, its 30 day story count is now at 7.
  • Over the past 12 days, the trend for UBX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about UBX are AGE, AMD and DE.

Latest UBX News From Around the Web

Below are the latest news stories about Unity Biotechnology Inc that investors may wish to consider to help them evaluate UBX as an investment opportunity.

UNITY posts 24-week data from Phase 1 trial for UBX1325 in vascular eye diseases

UNITY Biotechnology <> announced 24-week data from its Phase 1 study for UBX1325 in patients with diabetic macular edema ((DME)) and wet age-related macular degeneration (wet…

Seeking Alpha | February 14, 2022

UNITY Biotechnology Announces Additional Data from Phase 1 Study of UBX1325 in Advanced Vascular Eye Disease

24-week UBX1325 Phase 1 data presented at Angiogenesis, Exudation, and Degeneration 2022 Conference Patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD) showed improvement in visual acuity through 24 weeks following single dose of UBX1325 Phase 2 clinical studies of UBX1325 currently enrolling patients with DME and wAMD SOUTH SAN FRANCISCO, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company de

Yahoo | February 14, 2022

H.C. Wainwright Thinks Unity Biotechnology’s Stock is Going to Recover

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Unity Biotechnology (UBX – Research Report), with a price target of $12.00. The company's shares closed last Monday at $1.02, close to its 52-week low of $1.00. According to TipRanks.com, Fein is ranked 0 out of 5 stars with an average return of -3.2% and a 34.8% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA - American, Amylyx Pharmaceuticals, Inc., and Deciphera Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Unity Biotechnology with a $6.

Christine Brown on TipRanks | February 7, 2022

Mizuho Securities Thinks Unity Biotechnology’s Stock is Going to Recover

In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Unity Biotechnology (UBX – Research Report), with a price target of $7.00. The company's shares closed last Friday at $1.02, close to its 52-week low of $1.00. According to TipRanks.com, Syed is ranked 0 out of 5 stars with an average return of -14.1% and a 37.5% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Assembly Biosciences, and Coherus Biosciences. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Unity Biotechnology with a $5.00 average price target, implying a 371.

Catie Powers on TipRanks | February 4, 2022

Anti-aging company Unity Biotechnology to axe half its staff, focus on eye drugs

The quest to ease the pain of aging baby boomers and future generations hasn't translated into much clinical success. But as pioneering aging disease companies switch gears, startups continue to jump in.

Yahoo | February 3, 2022

UNITY Biotechnology Announces Restructuring to Advance Corporate Strategy and Focus on Key Ophthalmology Programs

Strategic realignment to focus capital resources on clinical programs and extend cash runway into Q1 2023 12-week data from Phase 2a study of UBX1325 in diabetic macular edema (DME) expected mid-2022 16-week data from Phase 2 study in wet age-related macular degeneration (wet AMD) expected in Q4 2022 SOUTH SAN FRANCISCO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases o

Yahoo | February 3, 2022

Arbor Wealth Management, LLC Buys Wells Fargo, Activision Blizzard Inc, Amcor PLC, Sells Altice ...

Investment company Arbor Wealth Management, LLC (Current Portfolio) buys Wells Fargo, Activision Blizzard Inc, Amcor PLC, Consolidated Edison Inc, Take-Two Interactive Software Inc, sells Altice USA Inc, Putnam Premier Income Trust, Unity Biotechnology Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Arbor Wealth Management, LLC.

Yahoo | January 25, 2022

Analysts’ Top Healthcare Picks: Allena Pharmaceuticals (ALNA), Unity Biotechnology (UBX)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Allena Pharmaceuticals (ALNA – Research Report) and Unity Biotechnology (UBX – Research Report) with bullish sentiments. Allena Pharmaceuticals (ALNA) Wedbush analyst Liana Moussatos reiterated a Buy rating on Allena Pharmaceuticals today and set a price target of $4.00. The company's shares closed last Tuesday at $0.58. According to TipRanks.

Howard Kim on TipRanks | January 5, 2022

UNITY Biotechnology Provides Program Updates and Anticipated Milestones for 2022

12-week safety and efficacy analysis from a Phase 2 study of UBX1325 in diabetic macular edema (DME) expected in first half 2022 and wet age-related macular degeneration (wet AMD) expected in the second half of 2022 Phase 2 study of UBX1325 in wet AMD to include comparison with aflibercept Additional pipeline programs targeting age-related diseases continue to advance SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology

Yahoo | January 4, 2022

UNITY Biotechnology Reports Granting of New Employment Inducement Award

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from December 7, 2021, through December 21, 2021, the Compensation Committee of the Board of Directors (the Board) granted a new employee a stock-based award covering an aggregate of 4,500 shares of UNITY common stock, including options to purchase an aggregate of 4,500 shares of UNITY common stock. The stock-based award was granted pursuant to the UNITY 2020 Employment Inducement Incentive Plan, as amended, which was approved by the Board in March 2020 to provide for grants to newly hired employees as a material inducement for them to commence employment with UNIT...

Intrado Digital Media | December 22, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5855 seconds.